CytomX Therapeutics CTMX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's free cash flow?
- CytomX Therapeutics (CTMX) reported free cash flow of -$25.55M in Q1 2026.
- How has CytomX Therapeutics's free cash flow changed year-over-year?
- CytomX Therapeutics's free cash flow decreased by 20.7% year-over-year, from -$21.16M to -$25.55M.
- What is the long-term trend for CytomX Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), CytomX Therapeutics's free cash flow has grown at a -11.0% compound annual growth rate (CAGR), from -$120.64M to -$75.81M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.